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Abstract
The medications used in asthma have been the subject of intense study over the last three decades. We now have extensive insights 
into their structure, regulation, receptors and mechanisms of action. Their intersection with the complexity of asthma inflammation 
has also been well characterised. In parallel, good quality pharmaceutical trials have informed national guidelines and patient-
centered outcomes have been explored. With this therapeutic armamentarium the practitioner should aim to achieve the goals 
of asthma therapy that are focused on clinical and lung function parameters. The concept of complete asthma control is the current 
benchmark.   
Airway inflammation is the fundamental problem in asthma and, logically, anti-inflammatory therapy in the form of inhaled corti-
costeroids is the single most important intervention. The importance of appropriate use of inhaler devices cannot be sufficiently 
emphasised. The clinician carefully titrates this treatment utilising additional medications for synergy and to modulate side-effects 
and costs. The contemporary standard of asthma care is a single inhaler with a combination of inhaled corticosteroids (ICS) and long-
acting beta adrenoceptor agonists. The alternative is to add leukotriene modifiers to ICS therapy; there are special circumstances 
when this may be more appropriate. Poor inhaler use and concomitant allergic rhinitis are examples when supplementation with 
anti-leukotriene agents would be prudent. With whatever therapeutic strategy, regular education of the patient, tailoring of medication 
and monitoring of asthma are still crucial to ensure that the goals of asthma control are achieved and maintained in the long term. 
 This article has been peer reviewed. Full text available at www.safpj.co.za SA Fam Pract 2008;50(4):28-36
Introduction
Allergic sensitisation in atopic individuals sets the stage for the 
initiation and perpetuation of a series of events at cellular level in the 
bronchi and lungs that manifest as asthma. Over the last 20 years 
a bewildering number of genetic factors and a veritable arsenal of 
inflammatory pathways and mediators have been and continue to be 
discovered.1,2  The clinician does not, in general, need to encompass 
this complexity – suffice to appreciate that at the core of asthma is 
the interaction of these components – airway inflammation. This is 
associated with bronchial hyper-responsiveness and episodic airway 
narrowing that are expressed in the clinical diagnosis of asthma. Pari 
pasu with the scientific research has been the concomitant elucidation 
of pharmacologic mechanisms and the therapeutic choices are now 
beyond question. 
Corticosteroids 
Corticosteroids (CS) have emerged as the most effective anti-
inflammatory agents for chronic persistent asthma. 3 The end result of 
a variety of inflammatory stimuli is to programme the nuclei of immune 
cells towards the production of a host of pro-inflammatory mediators 
and to overwhelm anti-inflammatory mechanisms. We now understand 
that the best way to counteract this deleterious state is to administer 
corticosteroids. Steroids act through both genomic and non-genomic 
pathways. 4 Some of the non-genomic actions control inflammatory 
pathways. However, their principal action is genomic. This is initiated 
by the entry of steroids into cells and their subsequent linkage and 
activation of cytoplasmic (hitherto inactivated) glucocorticoid receptors 
(GR). These activated complexes translocate to the nucleus where 
binding to the promoter regions of DNA associated with the production 
of pro-inflammatory mediators is substantially reduced. Simultaneously 
the production of anti-inflammatory mediators is enhanced - the net 
effect is a dampening of inflammation.
Steroids are best administered by the inhaled route; this allows for 
targeted therapy at the site of disease and a substantial decrease in 
dosage (it is oral steroids that are primarily associated with the well 
known Cushingoid phenotype – not the inhaled form). Interestingly, 
one of the problems of inhaled therapy is that they are rapidly cleared 
from the airways by the bronchial circulation. One of the reasons 
that CS remain resident in the airways for a longer time is because 
they induce bronchial mucosal vasoconstriction thus impairing 
clearance of the medication. 5 We should remember that historically, 
steroid potency was determined by the McKenzie skin test. 6 Here, 
steroids are applied topically to the skin and their potency measured 
by the area of blanching induced (through vasoconstriction); for 
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equivalent concentrations of drugs, the larger the area, the more 
potent the steroid. This property of steroids likely improves the clinical 
effectiveness in the airways in asthma. 
Another method to increase steroid activity is to develop agents that 
bind with increased affinity to the receptor: the stronger and longer the 
association with the GR, the more prolonged the anti-inflammatory 
effect.7 Des-ciclesonide (the active moiety of ciclesonide [Alvesco®]), 
fluticasone propionate and budesonide are amongst the most potent in 
this regard. This relative receptor affinity translates to dose equivalents 
of ICS. (Table I)
Table I:  Clinical dose-equivalents of different corticosteroids
Steroid Preparation Clinical  Dose-equivalents
Beclomethasone dipropionate 250 µg
Budesonide 200 µg
Fluticasone propionate 100 µg
Ciclesonide   80 µg
The clinical dose-equivalents of different corticosteroids used in 
asthma are based on their relative receptor affinities for the steroid 
receptor. The more avid the binding, the more potent the clinical effect.
The final mechanism whereby steroids have an increased duration 
of action is reversible esterification.8 Here, when a dose of steroid is 
administered, some molecules bind immediately to GR whilst others 
bind to fatty acid esters in the tissue which then acts as a “reservoir” of 
the drug. They can dissociate from the ester and become available to 
bind to GR at the later stage after the initially GR bound drug has been 
metabolised. This is relevant for budesonide and ciclesonide. 
Despite their potency, the vast majority of inhaled steroids need 
currently to be given twice daily.
Ultra-long acting steroids that will remain bound to the steroid receptor 
for up to 24 hours allowing for once daily dosing are in development. 
Assessing the efficacy of ICS
We do not, as yet, have simple tools to measure airway inflammation. 
The clinician uses surrogate markers. As inflammation is brought under 
control there is an accompanying decrease in asthma symptoms and 
the need for short-acting rescue β2 agonist use (salbutamol). Thus the 
doctor deduces the degree of airway inflammation by the frequency of 
salbutamol usage; frequent, daily use is an indication to increase the 
ICS dose. The second way to monitor airway inflammation is serial 
peak expiratory flow rate (PEFR) monitoring.
Again, as inflammation subsides, the airways spontaneously dilate. 
Therefore reviewing pre-bronchodilator PEFR over time reflects the 
adequacy of ICS treatment. Determining post- bronchodilator PEFR 
is also useful: the magnitude of change may also be dependent on 
inflammation – the better the control, the better the bronchodilator 
response. One can then, over time, determine the personal best lung 
function that the patient should achieve and maintain. 
ICS are extremely safe. There is negligible systemic toxicity with 
conventional doses (again it is inadequate control of asthma and the 
need to use systemic steroids that contribute to systemic adverse 
effects). With high dose ICS there is a very low prevalence of 
cataracts, skin bruising, growth problems and adrenal suppression. 
Local side-effects such as pharyngeal candidiasis and laryngeal 
problems can be avoided with spacer devices and mouth gargling. If, 
despite these measures, these remain problematic, then an agent such 
as ciclesonide should be tried as it is mainly activated in the lungs and 
not at the level of the pharynx. 
 
β2- adrenoceptor agonists
β2-adrenoceptor agonists work via cell surface β2-receptors that 
signal via cyclic AMP to cause smooth muscle relaxation. These are 
available as either short acting or long acting formulations (SABA or 
LABA). SABA may be used as needed or regularly – the former being 
advocated because of the concerns over tolerance. However, a large 
meta-analysis has shown no differences with either approach; clinical 
outcomes are equivalent with no danger of precipitating exacerbations 
with regular use.9 Occasionally, regular treatment produces better 
asthma control scores.10 
One of the disadvantages with as needed SABA prescription is under-
usage. It is well known that some asthmatics are under-perceivers of 
airway narrowing.11 These subjects fail to appreciate a reduction of up 
to 50% of airflow and hence do not use SABA when they ought to be 
doing so. Again, regular PEFR monitoring will alert clinicians to this 
problem; if the PEFR is low and the patient denies symptoms, these 
patients, in particular, should take their SABA regularly. 
If subjects do not achieve asthma control at a dose of 400-800 µg/d 
of budesonide/equivalent, then international and national guidelines 
recommend the addition of LABA as the best therapeutic option.12,13 
Those follow the excellent control and reduction in exacerbations seen 
with ICS/LABA.
The reason for this observation lies in the in-vitro demonstration of 
the pharmacological synergy of these two agents. CS increases the 
production and improves the function of beta adrenergic receptors 14, 15 
and LABA augment the anti-inflammatory action of corticosteroids. The 
latter is achieved by increasing the translocation of activated steroid 
receptors into the nucleus to block inflammatory mediators. 16, 17 The 
prolonged bronchodilator properties of LABA did raise the concern that 
they may mask inflammation, however, provided an adequate dose of 
corticosteroids is used, it is now proven that this does not occur and 
that the synergy results in improved pathological control.18
When compared to leukotriene modifiers a Cochrane meta-analysis 
has shown superiority of LABA in improving lung function and 
symptoms, need for rescue therapy and exacerbation reduction. 19 
LABA have an excellent safety profile and reports of their association 
with asthma mortality are completely unjustified. Formal audits of 
their use have shown no link with asthma mortality. 20, 21 Deficiencies 
in healthcare delivery and improper prescribing are contributors to 
asthma mortality. 22 It has long been established that over-reliance or 
exclusive prescription of bronchodilators alone are linked to asthma 
mortality. It is always imprudent not to utilise ICS in chronic asthma.
Combination LABA+ ICS products 
Fixed dose single inhaler devices that contain both ICS and LABA 
are also very effective in achieving asthma control.23 A major problem 
that bedevils asthma is the frequent occurrence of non-adherence of 
the ICS inhaler with separate inhalers.24 The convenience of a single 
inhaler improves compliance and ensures that patients do not omit 
their ICS treatment. Simplifying the regimen is an important principle, 
particularly in the face of poly-pharmacy when there are co-morbid 
conditions.  
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Two effective strategies using combination inhalers are possible: 
i)  Step-up fixed dose regimen with sequential increasing of the ICS 
component to achieve control (Seretide® and Symbicord®): In the 
GOAL study (Gaining Optimal Asthma Control), Seretide® was 
compared to fluticasone propionate and as needed salbutamol. 25 
The fixed dosed strategy resulted in dramatically improved levels 
of asthma control that was attained faster and with lower steroid 
doses than with fluticasone alone.  
ii)  The Single Inhaler Therapy (SIT) utilising the SMART approach- 
(Symbicord® for maintenance and reliever therapy): Here, the 
patient uses the combination inhaler twice a day and importantly, 
the same inhaler for rescue use.26 It would appear counter intuitive 
that the approach seems to be driven by symptoms; real world 
experience has shown otherwise. Clinical control as measured by 
symptom free days, day and night scores and exacerbation rates 
compares favourably to fixed dose regimens.27 The rationale is that 
the need for rescue with SABA is frequently a signal of increased 
inflammation and that both agents are needed when there are 
wheezing episodes. Thus the correct timing of the increased need 
and dosage of steroids appears to support the hypothesis. In 
addition to good control, the overall steroid dose over time is also 
reduced compared to conventional regimens.27
Leukotrienes modifiers 
Arachidonic acid peroxidation results in either prostaglandin or 
leukotriene (LT) synthesis. Both play a role in asthma but the 
development of novel agents to modify LT actions has provided new 
insights into asthma. LTs mediate both allergic inflammation and 
bronchoconstriction.28
However, being highly selective, they do not have the wide spectrum 
of anti-inflammatory effects that ICS have and should not be used as 
monotherapy. Conversely, ICS have little or no effect on the leukotriene 
pathway.29 Leukotriene antagonists are therefore appropriately 
prescribed as add on therapy to 400-800µg budesonide. Long term 
clinical trials have demonstrated their non-inferiority to other strategies 
for combination therapy.  
In the COMPACT study, (Clinical Outcomes with Montelukast as a 
Partner Agent to Corticosteroid Therapy) patients not controlled on 
budesonide 800 µg alone were compared to the guideline strategy of 
doubling the dose of budesonide (1600 µg) or the addition of 10 mg 
montelukast.30 Montelukast promptly improved baseline lung function 
(because of its bronchodilator properties) and showed identical trends 
in improvement in all components of asthma control compared to 
the higher dose ICS. Similar observations have been reported with 
zafirlukast.31 
In the CASIOPEA study montelukast was added to symptomatic 
subjects on budesonide 400–1600 µg daily.32 Morning PEFR and 
asthma-free days increased, with fewer nocturnal awakenings, a 
reduction in SABA usage and a mild reduction in exacerbations also 
being documented. Importantly, some subjects with normal lung 
function were still able to achieve additional benefits. This emphasises 
the need to assess asthma control in a composite manner and 
that benefits over and above lung function are possible. Thus the 
prescription of this class of drug is preferable to doubling the dose of 
ICS. 
The IMPACT study (Investigation of Montelukast as a Partner Agent 
for Complementary Therapy) demonstrated equivalent efficacy in 
asthma outcomes between salmeterol and montelukast when added 
to low dose fluticasone propionate.33 Other advantages/roles for anti 
leukotrienes are 
1.  Oral use. This is particularly useful for those who cannot use/
comply with inhaled therapy
2. Exercise induced asthma 
3. Aspirin sensitive asthma (this is exclusively leukotriene mediated) 34
4. Negligible side-effects 
5. Concomitant allergic rhinitis
Co-existent allergic rhinitis and asthma reinforces the “united airway” 
hypothesis where the one entity has an influence on the other. It 
has been postulated that uncontrolled allergic rhinitis influences the 
manifestation of asthma. Studies with montelukast have lent credence 
to this. Firstly, it can be as effective as antihistamines and allow a dose 
reduction of nasal corticosteroids in allergic rhinitis.35 More importantly, 
when the allergic rhinitis is treated with montelukast, asthma control as 
measured by symptom scores, SABA usage, oral or ICS dosage and 
healthcare utilisation, all decreased.36 
Anti leukotrienes agents are extremely safe; there is probably no 
causal association with the Churg-Strauss Syndrome (CSS). A review 
of all putative reports have suggested that the use of leukotriene 
modifiers and concomitant reduction in corticosteroids unmasked a 
pre-existing Churg Strauss diagnosis or that the leukotriene modifiers 
were initiated in patients who were in the process of developing CSS.37
Theophylline
Theophylline probably mediates its effects via adenosine receptors 
and now that it is established that at therapeutic doses no 
phosphodiesterase inhibition occurs, this mechanism, in asthma, 
should no longer be perpetuated.38 It has bronchodilator and anti-
inflammatory properties as well; the latter effects being seen at lower 
doses than conventionally used.39 However, these features are weak 
and hence theophylline should not be considered as the sole controller 
agent for asthma. 
Theophylline can also have significant gastrointestinal, cardiac and 
neurological side-effects especially with other drugs that interfere 
with its hepatic metabolism viz cimetidine and some macrolides and 
quinolones. These, coupled with the safety and clinical superiority of 
LABA as add-on therapy to ICS, have relegated theophylline to the 
last choice when considering additional therapy. However, because 
they are relatively cheaper, they are more commonly used. When 
considering their prescription, the slow-release preparations are 
preferred. They are also beneficial in more severe asthmatics where 
they have been shown to be equivalent to doubling the dose of ICS.41   
They can also be steroid-sparing thus limiting the adverse-effect profile 
in oral- steroid dependent asthmatics.42 
Anti-cholinergic agents 
Anti- cholinergic agents work by blocking muscarinic receptors 
resulting in bronchodilation.43 However, they are less potent as SABA 
and when used in combination may produce little additional benefit.44 
Therefore the effectiveness of their prescription should be objectively 
measured and only maintained if a positive effect is documented. 
Situations that may permit their usage include the older asthmatic, 
severe asthma, intolerance to SABA and nocturnal symptoms.43
Other medications
The cromones such as sodium cromoglycate and nedocromil sodium 
have weaker anti-inflammatory properties than corticosteroids, limited 
CPD Article
SA Fam Pract 2008                  Vol 50 No 434
long-term efficacy data and currently have a minor role in the treatment 
of asthma.45
As regards oral steroids, these can have considerable side-effects 
and should not be used routinely. Their ease of use and relative cost 
have led to widespread abuse especially among patients who prefer to 
self -medicate. One should always consider adequate education and 
oral-steroid sparing strategies to limit complications. Short courses are 
appropriate for exacerbations and the minimal effective maintenance 
dose in the very difficult to treat asthmatic.
Figure I:  Diagram to illustrate the dual components of asthma: smooth 


















Bronchodilatation: Theophylline acts via adenosine receptors (A), LABA/SABA 
via β2- adrenoceptors (B) and ipratropium via muscarinic (M) receptors.
—  Denotes inhibition.
Clinical practice and asthma
One would imagine that with the knowledge expounded thus far, there 
would be no problems with asthma control. This couldn’t be further 
from the truth. Appropriate understanding of the disease process and 
pharmacology should allow us to achieve the therapeutic targets that 
are the composite of asthma control (Table II). But, as with all areas 
of medicine, there are numerous barriers to effective clinical practice. 
Repeated audits of adherence to guidelines, prescriptions and patient 
experiences have revealed that we are far from optimising asthma 
care.46 What are some of the major issues? Firstly, many doctors 
are not aware of the clinical studies, do not prescribe according 
to guidelines and accept sub-optimal asthma control. Secondly, 
patients have also decreased their expectations and accept that 
they will continue to have symptoms that limit their lifestyles. Thirdly, 
the clinicians and scientists themselves confuse colleagues when 
performing studies where asthma outcomes are not standardised or 
calibrated to therapy.47,48 
Table II: Therapeutic targets in asthma
Complete amelioration of symptoms 
Minimal need for rescue SABA use
Normal or personal best lung function
No exacerbations 
No lifestyle restrictions 
Reduced likelihood of side-effects of therapy 
The New England Journal of Medicine suggested that intermittent ICS 
usage was satisfactory when this strategy failed dismally in a package 
of asthma control parameters.48 Szefler et al,47 studied the numbers 
of patients responding to ICS and montelukast and found it to be a 
maximum of 40% and 23% respectively. However, a response was 
defined as a pre-bronchodilator FEV1 ≥ 7.5%; most of the subjects 
were mild asthmatics with FEV1 approximately 100% and therefore it 
is conceivable that this value could not be improved upon. In clinical 
practice almost all asthmatics will have some response to steroids. 
Finally, health systems need to support and fund the most cost 
effective therapies. This is not currently the case.   
Conclusion
Addressing inflammation is the most important aspect of asthma 
treatment. The doctor uses his understanding of asthma therapies 
and surrogate clinical markers to decide whether the goals of asthma 
have been met. The importance of education and training in proper 
inhaler technique must not be under estimated. Poor asthma control 
is frequently a consequence of poor technique and adherence. One 
could prescribe the most innovative medication and inhaler device but 
these would be completely ineffective if not used appropriately. A useful 
maxim to patients is “the better you use your inhaler, the better the 
relief you’ll experience and the better will be your quality of life”.  
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